About Alzamend Neuro, Inc.

Share
img

What is Alzheimer's disease?

Alzamend Neuro™ is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses

Pipeline LEARN MORE

Statistics

  • 13 million

    The number of Americans projected to be living with Alzheimer’s disease by the year 2050

  • 6.2 million

    The number of Americans projected currently living with Alzheimer’s disease in 2021

  • 11 million

    The number of Americans that provide unpaid care for people with Alzheimer’s or other Dementias

  • Ranks 6th

    Leading cause of death in the U.S.

  • 1-in-3

    The estimated number of seniors that will die with Alzheimer’s disease or another dementia

  • Ranks 5th

    Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans

  • $355 billion

    The estimated cost in 2021 of Alzheimer’s disease to the United States.

  • $257 billion

    The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends

  • $1.1 trillion

    The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found

  • 1-in-9

    The estimated number of Americans age 65 and over that are afflicted in 2021 with Alzheimer’s disease

Share

Press Releases

LEARN MORE ALL UPDATES

Making Alzheimer's Just a Memory®

  • Copyright © 2016 - 2022 Alzamend Neuro Inc. All rights reserved.